1. A184 EARLY SYMPTOM CONTROL WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT-1 INDUCTION TRIAL. (7th March 2023) Authors: Danese, S; Dignass, A; Matsuoka, K; Ferrante, M; Long, M; Redondo, I; Gibble, T H; Moses, R; Morris, N; Li, X; Milch, C; Abreu, M; Jones, J Journal: Journal of the Canadian Association of Gastroenterology Issue: Volume 6(2023)Supplement 1 Page Start: 28 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A185 SUSTAINED SYMPTOM CONTROL WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT-2 MAINTENANCE TRIAL. (7th March 2023) Authors: Dignass, A; Danese, S; Matsuoka, K; Ferrante, M; Long, M; Redondo, I; Gibble, T H; Moses, R; Li, X; Morris, N; Milch, C; Abreu, M; Jones, J Journal: Journal of the Canadian Association of Gastroenterology Issue: Volume 6(2023)Supplement 1 Page Start: 29 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. DOP86 Mirikizumab-induced upregulation of colonic transcripts correlates with improvements in stool frequency in a phase 2 study of patients with moderately to severely active Ulcerative Colitis. (21st January 2022) Authors: Steere, B; Powell, N; Higgs, R; Wang, Y C; Milch, C; Sandborn, W J; Sands, B E; Reinisch, W; D'Haens, G; Krishnan, G Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i129 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. OP26 Efficacy and safety of mirikizumab as induction therapy in patients with moderately to severely active Ulcerative Colitis: Results from the Phase 3 LUCENT-1 study. (21st January 2022) Authors: D'Haens, G; Kobayashi, T; Morris, N; Lissoos, T; Hoover, A; Li, X; Arora, V; Milch, C; Sandborn, W J; Sands, B E Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i028 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. OP28 Gene expression (GE) values in a phase 2 trial of mirikizumab in ulcerative colitis (UC) correlate better with histopathology (HP) than endoscopy (EN) and Mayo scores. (15th January 2020) Authors: Steere, B; GOTTLIEB, K; Schmitz, J; Higgs, R; Jia, B; Milch, C; Tuttle, J; Krishnan, V; Belin, R; Reinisch, W Journal: Journal of Crohn's and colitis Issue: Volume 14(2020)Supplement 1 Page Start: S025 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P255 Mirikizumab modulates genes associated with the symptom of bowel urgency. (21st January 2022) Authors: Krishnan, G; Steere, B; Higgs, R; Wang, Y C; Harris, C J; Milch, C; Escobar, R; Reinisch, W; Dubinsky, M Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i297 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P471 A Transcriptome-dependent Prognostic Model of Response in Patients with Ulcerative Colitis. (30th January 2023) Authors: Johnson, T; Reinisch, W; Steere, B; Milch, C; Harris, C; Morris, N; D'Haens, G; Huang, K; Krishnan, V Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i600 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. The Alte Schäfflerei at Benediktbeuern Monastery – Conjunction of Architectural Conservation and Energy Performance Improvement in a Historic Buildings. Issue 1 (October 2021) Authors: Kilian, R; Bichlmair, S; Krus, M; Merktle, D; Milch, C; Sedlbauer, K P Journal: IOP conference series Issue: Volume 863:Issue 1(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗